Core Insights - In June 2025, over 500 FOF funds had an average return of 2.11% and a median return of 1.83%, while the CSI 300 index rose by 2.5% [1] - More than 90% of FOF funds achieved positive returns in June, with notable performers including Guotai's Preferred Navigation One-Year Holding and others exceeding 7% returns [1][2] - Some FOF funds, particularly those newly established, underperformed, with institutions like Dongfanghong Asset Management and Qianhai Kaiyuan Fund showing weaker results [1][10] Performance Summary - Guotai Preferred Navigation One-Year Holding achieved a return of 9.26% in June, with a cumulative return of 11.11% for the first half of 2025 [6] - Other high-performing funds included Guotai Industry Rotation A at 8.02%, and Jiao Yin Smart Selection at 7.31% [2] - A list of top-performing FOF funds in June includes several with returns exceeding 20%, such as Yongying Technology Smart Selection A at 37.21% [3][4] Underperforming Funds - Some FOF funds experienced slight losses, with the worst performer, Dongfanghong Yingfeng Stable Allocation, showing a decrease of 0.04% [13] - Newly established funds, such as Qianhai Kaiyuan Kangyue Stable Pension One-Year Holding, also reported minimal gains, indicating challenges in early performance [10][13] - The underperformance of certain funds is attributed to their recent establishment and lack of substantial asset bases [10][13]

每经记者｜任飞 每经编辑｜赵云 上周，医药板块整体继续上涨，带动基金业绩水涨船高，一众重仓医药基金的公募FOF跻身周收益排名前列。 对于这波行情，业内仍存不小分歧。一部分看好医药行业价值的重估已经开启；另一部分谨慎者则担心，空头出清 的尾声依然没有结束。但从中长期来看，国内的创新药国际竞争力增强也是国内外资本持续看好的关键因素。 医药行情持续，这些FOF跻身周收益排名前列 过去两三年，无论买方还是卖方机构的研究员、基金经理，都在表态医药行业即将"否极泰来"，但又"年年期望年年 失望"，直到2025年，情况变得不一样了——近期，"吃药行情"持续演绎。 Wind统计显示，汇添富香港优势精选A大涨78.8%，长城医药产业精选A、永赢医药创新智选A、华安医药生物A等多 只医药主题基金年内涨幅超60%。可以说，医药股特别是一些创新药标的恰似前些年的AI概念股，资金源源不断地 对其进行关注。 而在公募FOF领域，近期也有一些重仓医药基金的FOF业绩领先。上周，混合型FOF的周收益第一名为国泰优选领航 一年，单周收益率达到4.56%，领先第二名交银智选进取三个月A近2个百分点，重仓的基金中就有医药基金。 截至今年一季度末， ...